The effect of sodium nitrite infusion on renal function, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamide in healthy subjects: a randomized, double-blinded, placebo-controlled, crossover study

Table 3 Effect of intravenous NaNO₂ on combined nitrate and nitrite (NOx) and cGMP

	Baseline	Infusion		Post-infusion	p _{RM ANOVA (one-way)}
	Baseline	60 min	120 min	180 min	p _{RM ANOVA (one-way)}
P-NO_x (μmol/l)
Placebo	17 (13;21)	25 (19;31)^*	31 (24;38)^*	29 (22;35)^*	<.001
Allopurinol	17 (14;23)	24 (19;30)^*	32 (26;36)^*	30 (26;32)^*	<.001
Enalapril	15 (12;19)	24 (21;31)^*	29 (26;32)^*	27 (24;31)^*	<.001
Acetazolamide	17 (13;19)	24 (21;31)^*	30 (27;35)^*	27 (23;32)^*	<.001
p_{interaction (pretreatment x time)}		.742
U-NO_x (μmol/min)
Placebo	0.52 (0.37;0.69)	0.72 (0.52;0.79)^*	0.94 (0.88;1.09)^*	0.95 (0.83;1.21)^*	<.001
Allopurinol	0.60 (0.42;0.88)	0.79 (0.65;0.98)^*	0.99 (0.87;1.23)^*	1.07 (0.90;1.18)^*	<.001
Enalapril	0.57 (0.44;0.78)	0.69 (0.59;0.97)^*	0.99 (0.87;1.22)^*	0.94 (0.80;1.31)^*	<.001
Acetazolamide	0.49 (0.45;0.54)	0.63 (0.59;0.67)^*	0.98 (0.86;1.05)^*	0.94 (0.85;1.06)^*	<.001
p_{interaction (pretreatment x time)}		.677
P-cGMP (pmol/ml)
Placebo	88 [78;98]	93 [83;104]	87 [78;95]		.310
Allopurinol	91 [83;100]	87 [77;98]	88 [77;98]		.597
Enalapril	82 [71;92]	85 [74;96]	93 [75;110]		.102
Acetazolamide	90 [78;101]	84 [74;93]	84 [74;94]		.088
p_{interaction (pretreatment x time)}		.111
U-cGMP (pmol/min)
Placebo	425 (356;530)	426 (371;561)	414 (341;515)	321 (235;343)^*	<.001
Allopurinol	487 (388;613)	453 (353;575)	461 (376;570)	367 (287;443)^*	<.001
Enalapril	404 (291;527)^†	425 (329;552)	409 (309;486)	284 (243;349)^*	<.001
Acetazolamide	361 (305;484)^†	345 (296;468)	372 (325;470)	269 (236;324)^*	<.001
p_{interaction (pretreatment x time)}		.362

Effect of intravenous NaNO₂ on plasma concentrations (n = 16) and urinary excretion rates (n = 14) of combined nitrate and nitrite (NO_x) and guanosine 3′,5′-cyclic monophosphate (cGMP) in healthy subjects after 4 days pretreatment with allopurinol, enalapril, acetazolamide, or placebo. Normal distributed data are presented as means with 95% confidence interval in brackets and non-parametric data as medians with 25th and 75th percentiles in parentheses. Statistics were performed using one-way repeated measures (RM) ANOVA for comparing over time and two-way RM ANOVA with time and pretreatment as within factors to test for interaction. Pairwise comparison where performed using Student’s t-test. P-NO_x, U-NO_x and U-cGMP were log transformed prior to testing
^* p < .05 within group vs. baseline (Bonferroni), ^† p < .05 vs. placebo at baseline

ISSN: 1471-2369